Laurus Labs Ltd
Laurus Labs Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
CDMO segment is expected to grow significantly, driven by ongoing and new projects with big pharma partners, including human health, animal health, and crop sciences divisions. Laurus Labs expects significant growth in revenues and profitability in FY26 compared to FY25, driven notably by the CDMO and formulation segments.
From Laurus Labs Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO segment is expected to grow significantly, driven by ongoing and new projects with big pharma partners, including human health, animal health, and crop sciences divisions.
- CDMO revenue contribution increase anticipated to improve overall margins.
- ARV revenues expected to remain stable around INR 2,500-2,600 crores in the medium term; no major growth expected there.
- Non-ARV formulations sales to rise, especially from approvals in US and Canada and new CMO contracts.
- Animal health business to see a significant revenue jump by FY26 post commercial validations.
- Crop sciences business is nascent, expected to mature over next year for clearer outlook.
- Capex focused on CDMO/CMO expansions, expected to fuel growth in these segments.
2 more points from Laurus Labs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY26 capex is planned around INR1,000 crores.
- Major capex focus areas include:
- Increasing formulation CMO capacity.
- Specific capex for a formulation partner.
- Fermentation capacity expansion in Vizag with close to INR250 crores.
- Adding production blocks at Vizag for API and CDMO businesses.
- No significant increase in debt is expected to support this capex.
- No new greenfield facilities are expected to start operations in FY26; expansion is mostly through existing sites.
- INR5,000 crores capex announcement includes backward integration and de-risking the supply chain to reduce dependence on China.
2 more points from Laurus Labs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The active pipeline projects have increased significantly to 110 currently, up from around 60 two to three years ago.
- Out of the 110, about 90 projects are in human health and 20 in animal health.
- Majority of these projects are in advanced phases, primarily Phase 2 and Phase 3, indicating strong revenue potential.
- The number of Requests for Proposal (RFPs) has also seen a significant increase, signaling growing order intake.
- CDMO projects are long and complex with longer order-to-delivery timelines, contributing to higher working capital and backlog.
- Animal health CDMO is expected to see a significant revenue jump starting FY26 as validations complete and commercial production begins.
2 more points from Laurus Labs Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Laurus Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.8K Cr, net profit ₹282 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laurus Labs Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Laurus Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Laurus Labs Ltd Q4 FY25 results?
CDMO segment is expected to grow significantly, driven by ongoing and new projects with big pharma partners, including human health, animal health, and crop sciences divisions. Laurus Labs expects significant growth in revenues and profitability in FY26 compared to FY25, driven notably by the CDMO and formulation segments.
What is Laurus Labs Ltd share price analysis?
Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 88.3 with a market cap of ₹96,570 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laurus Labs Ltd planning capital expenditure?
FY26 capex is planned around INR1,000 crores.
Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.